Sara Singer, Nidhi Sharma, Robert Dean, Qiuhong Zhao, Donna Abounader, Patrick Elder, Craig C Hofmeister, Don M Benson, Ashley Rosko, Sam Penza, Leslie Andritsos, Sumithira Vasu, Samantha Jaglowski, Basem M William, Brian Bolwell, Brad Pohlman, Matt Kalaycio, Deepa Jagadeesh, Brian Hill, Ronald Sobecks, Steven M Devine, Navneet S Majhail, Yvonne A Efebera
High-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT) is an effective salvage therapy for patients with relapsed chemosensitive non-Hodgkin's lymphoma (NHL). However, the optimal conditioning regimen is unclear. Different conditioning regimens prior to AHCT have been used with the two most common being BEAM (carmustine, etoposide, cytarabine, and melphalan) and BUCYVP16 (busulfan, cyclophosphamide, and etoposide). We sought to compare the two regimens for patients with relapsed NHL undergoing AHCT...
October 2019: Bone Marrow Transplantation